|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400085208 |
|
最近更新日期: Date of Last Refreshed on: |
2024-06-03 14:39:20 |
|
注册时间: Date of Registration: |
2024-06-03 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
rTMS联合tDCS对老年认知障碍的疗效及机制研究 |
|
Public title: |
To develop the key technologies and systems for the assessment and early warning of elderly consciousness/cognitive impairment and multi-physical factor co-stimulation intervention——The study of the efficacy and mechanism of rTMS combined with tDCS in the treatment of elderly cognitive impairment |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
老年意识/认知障碍评估预警与多物理因子协同刺激干预关键技术及系统研发——rTMS联合tDCS对老年认知障碍的疗效及机制研究 |
|
Scientific title: |
The study of the efficacy and mechanism of rTMS combined with tDCS in the treatment of elderly cognitive impairment. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
叶子莹 |
研究负责人: |
胡昔权 |
|
Applicant: |
Ziying Ye |
Study leader: |
Xiquan Hu |
|
申请注册联系人电话: Applicant telephone: |
+86 156 2253 6954 |
研究负责人电话: Study leader's telephone: |
+86 189 2210 2910 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yeziyiing@163.com |
研究负责人电子邮件: Study leader's E-mail: |
huxiquan@mail.sysu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省广州市中山大学附属第三医院天河路 600 号 |
研究负责人通讯地址: |
中国广东省广州市中山大学附属第三医院天河路 600 号 |
|
Applicant address: |
Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Guangzhou, 510630, Guangdong, China |
Study leader's address: |
Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Guangzhou, 510630, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中山大学附属第三医院 |
||
|
Applicant's institution: |
Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China |
||
|
研究负责人所在单位: |
中山大学附属第三医院 |
||
|
Affiliation of the Leader: |
Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
中大附三医伦RG2024-023-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第三医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The Institutional Ethics Committee of The Third Affiliated Hospital of Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-02-29 00:00:00 |
||
|
伦理委员会联系人: |
黄凯琪 |
||
|
Contact Name of the ethic committee: |
Kaiqi Huang |
||
|
伦理委员会联系地址: |
广东省广州市天河路 600 号 |
||
|
Contact Address of the ethic committee: |
600# Tian He Road,Guangzhou, |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 85253302 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中山大学附属第三医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市天河路 600 号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Guangzhou, 510630, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2022YFC3601200 |
||||||||||||||||||||||
|
Source(s) of funding: |
2022YFC3601200 |
||||||||||||||||||||||
|
Target disease: |
Mild Cognitive Impairment/Alzheimer's disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
为解决老年认知障碍在评估、预警、干预方面的不足,本项目拟通过MoCA-B等相关量表,MRI、fNIRS、脑电等评估方法,明确rTMS与tDCS在老年轻度认知障碍中的联合疗效,并探究其可能的中枢机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
To address the shortcomings in the assessment, early warning, and intervention of elderly cognitive impairment, this project aims to use scales such as MoCA-B, evaluation methods including MRI, fNIRS, EEG, etc., to clarify the combined efficacy of rTMS and tDCS in mild cognitive impairment in the elderly, and explore their potential central mechanisms. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①自愿参加并签署知情同意书时,受试者年龄≥60岁; ② 受试者或知情者报告其记忆功能出现渐进性和进展性的改变≥3月; ③ 存在轻度认知障碍或轻度至中度痴呆; ④ 具备足够的读写和视听能力,可以进行神经心理学测试; ⑤ 如使用改善认知类药物(如多奈哌齐、美金刚),至少达3月及以上,入组期间不再进行剂量调整。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Volunteers who are aged 60 years or older and sign the informed consent form. 2. Subjects or informants report progressive and evolving changes in memory function for ≥3 months. 3. Presence of mild cognitive impairment or mild to moderate dementia 4. Sufficient reading, writing, and audio-visual abilities to undergo neuropsychological testing. 5. If using cognitive-enhancing drugs (such as donepezil, memantine), must have been on a stable dose for at least 3 months with no dosage adjustments during the enrollment period. |
||||||||||||||||||||||
|
排除标准: |
① 既往有脑肿瘤、脑外伤、脑卒中、癫痫、帕金森病或精神障碍等神经系统疾病; ② 既往有代谢性疾病,包括贫血、甲状腺功能障碍、叶酸、维生素B12缺乏等可导致认知下降的疾病; ③ 在筛选前2年内存在酗酒或吸毒史; ④ 开颅手术后/颅骨缺损; ⑤ 金属或电子装置植入物(例如心脏起搏器、耳蜗植入物、深部脑刺激器、动脉瘤夹、脑室腹腔分流术后内固定装置等); ⑥可能影响研究的其他严重疾病 ⑦同期参加其他临床研究者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. History of neurological diseases such as brain tumors, head trauma, stroke, epilepsy, Parkinson's disease, or mental disorders. 2. History of metabolic diseases including anemia, thyroid dysfunction, folate, vitamin B12 deficiency, and other conditions that can lead to cognitive decline. 3. History of alcohol abuse or drug use within the past 2 years before screening. 4. Post-craniotomy/cranial defect. 5. Presence of metal or electronic implants (e.g., pacemakers, cochlear implants, deep brain stimulators, aneurysm clips, internal fixation devices after ventriculoperitoneal shunt surgery, etc.). 6. Other serious illnesses that may affect the study. 7. Participation in other clinical studies concurrently. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-02-29 00:00:00至 To 2028-02-29 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-06-03 00:00:00 至 To 2028-02-29 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数表法 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲;研究对象和研究者都不了解试验分组情况,而是由研究设计者来安排和控制全部试验。 |
|
Blinding: |
Double blind;Neither the subjects nor the investigators knew the grouping of the trials, but the study designer arranged and controlled all the trials. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
如需原始数据,请与通讯作者联系 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
For raw data, please contact the corresponding author |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case record form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |